UFF
ENTA icon

USA Financial Formulas’s Enanta Pharmaceuticals ENTA Stock Holding History

USA Financial Formulas’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-5,579
Closed -$647K – 343
2018
Q3 		$647K Buy
+5,579
New +$559K 0.16% 93

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

USA Financial Formulas's ENTA Position: Q4 2018 in Review

USA Financial Formulas sold out of Enanta Pharmaceuticals (ENTA) in Q4 2018, closing a stake of 5,579 shares — an estimated $647K sold.

USA Financial Formulas first reported a position in ENTA in Q3 2018 and held it in 1 quarter. The position peaked at $647K in Q3 2018. 183 funds tracked by Wall St. Rank hold ENTA as of Q4 2018.

  • USA Financial Formulas reported no remaining Enanta Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • USA Financial Formulas sold 5,579 Enanta Pharmaceuticals shares in Q4 2018, an estimated $647K.
  • USA Financial Formulas first reported a position in Enanta Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • USA Financial Formulas's Enanta Pharmaceuticals position peaked at $647K in Q3 2018.
  • 183 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2018.

Based on USA Financial Formulas's 13F filing for Q4 2018, filed 14 Feb 2019.